Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.63

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been assigned an average rating of “Buy” from the eight ratings firms that are presently covering the stock, MarketBeat reports. Eight equities research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have covered the stock in the last year is $6.63.

TSHA has been the subject of several research reports. Canaccord Genuity Group increased their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Chardan Capital reiterated a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th.

Taysha Gene Therapies Trading Down 5.9 %

NASDAQ:TSHA opened at $1.75 on Thursday. Taysha Gene Therapies has a 52 week low of $1.19 and a 52 week high of $4.32. The firm has a 50-day moving average price of $2.12 and a two-hundred day moving average price of $2.24. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The firm has a market cap of $358.65 million, a price-to-earnings ratio of 2.78 and a beta of 0.79.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp purchased a new stake in shares of Taysha Gene Therapies during the second quarter valued at $1,018,000. Principal Financial Group Inc. purchased a new stake in shares of Taysha Gene Therapies during the 2nd quarter valued at about $48,000. Privium Fund Management B.V. bought a new stake in shares of Taysha Gene Therapies in the second quarter worth approximately $213,000. Rhumbline Advisers purchased a new position in shares of Taysha Gene Therapies during the second quarter valued at approximately $413,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Taysha Gene Therapies by 109.0% during the second quarter. The Manufacturers Life Insurance Company now owns 133,213 shares of the company’s stock valued at $298,000 after purchasing an additional 69,487 shares during the last quarter. 77.70% of the stock is owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.